ShinyHunters called cancer diagnostics biz and tricked staffers into giving them access. Now they’ve dumped 10.9M email addresses The Register
Startup OMass Secures $310M to Advance Drug for Rare Endocrine Disorder
OMass’s molecule is vying to become an alternative to a Neurocrine Biosciences drug that is currently the only FDA-approved therapy for congenital adrenal hyperplasia. But
